Amedisys Inc. (AMED) Trading Down 6.1%
Amedisys Inc. (NASDAQ:AMED) fell 6.1% during mid-day trading on Tuesday . The stock traded as low as $51.64 and last traded at $51.64, with a volume of 176,223 shares traded. The stock had previously closed at $55.00.
A number of research analysts have issued reports on AMED shares. Mizuho downgraded Amedisys from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $57.00 to $55.00 in a research note on Wednesday. Zacks Investment Research downgraded Amedisys from a “hold” rating to a “sell” rating in a research note on Monday, July 11th. Jefferies Group restated a “buy” rating and issued a $59.00 price objective on shares of Amedisys in a research note on Wednesday, May 25th. Stephens started coverage on Amedisys in a research note on Thursday, June 16th. They issued an “equal weight” rating and a $55.00 price objective for the company. Finally, Robert W. Baird restated a “hold” rating on shares of Amedisys in a research note on Monday, May 16th. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $51.75.
The stock has a market capitalization of $1.70 billion and a P/E ratio of 44.32. The firm has a 50-day moving average of $51.46 and a 200-day moving average of $46.46.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.42. During the same quarter in the previous year, the firm posted $0.43 EPS. The company had revenue of $360 million for the quarter, compared to analysts’ expectations of $353.07 million. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. Analysts forecast that Amedisys Inc. will post $1.73 earnings per share for the current fiscal year.
In other Amedisys news, insider Scott G. Ginn sold 6,000 shares of Amedisys stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $51.62, for a total transaction of $309,720.00. Following the completion of the transaction, the insider now owns 48,009 shares in the company, valued at $2,478,224.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce D. Perkins acquired 1,000 shares of the stock in a transaction on Friday, May 13th. The shares were bought at an average price of $50.21 per share, with a total value of $50,210.00. Following the purchase, the director now directly owns 10,354 shares of the company’s stock, valued at approximately $519,874.34. The disclosure for this purchase can be found here.
Other hedge funds and institutional investors recently made changes to their positions in the company. BlackRock Advisors LLC boosted its position in shares of Amedisys by 5.1% in the fourth quarter. BlackRock Advisors LLC now owns 931,832 shares of the company’s stock worth $36,640,000 after buying an additional 44,867 shares during the last quarter. TrimTabs Asset Management LLC bought a new position in shares of Amedisys during the fourth quarter worth about $2,169,000. Trexquant Investment LP bought a new position in shares of Amedisys during the fourth quarter worth about $1,031,000. Systematic Financial Management LP boosted its position in shares of Amedisys by 207.5% in the fourth quarter. Systematic Financial Management LP now owns 321,583 shares of the company’s stock worth $12,644,000 after buying an additional 217,008 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Amedisys by 4.7% in the fourth quarter. Principal Financial Group Inc. now owns 186,997 shares of the company’s stock worth $7,353,000 after buying an additional 8,329 shares during the last quarter.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.